01—Abstract
Summary
Summary of the 10-K filed February 21, 2017. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2016 10-K filing highlights a year of revenue growth, primarily driven by strong performance in the U.S. market, with a 14%a increase.
This growth was supported by key products like Trulicity, Taltz, and Jardiance, alongside the positive impact of acquiring commercialization rights for Erbitux in North America. However, the company faced significant headwinds from the loss of patent exclusivity for several products, including Cymbalta and Zyprexa in key markets, which led to substantial revenue declines for these specific drugs. The company continued its substantial investment in research and development, a core strategy for long-term competitiveness, with R&D expenses reaching $5.24 billionb.
Lilly also made strategic acquisitions, notably in its Elanco Animal Health division, to diversify its portfolio. A key focus for investors is the ongoing challenge of patent expirations and the company's ability to innovate and bring new products to market to offset these losses. The report also details ongoing patent litigation, product liability claims, and the impact of evolving healthcare regulations and payer pressures.
02—Key points
Key Highlights
- Total revenue increased by 6% to $21.22 billion in 2016, with U.S. revenue showing a strong 14% growth, largely driven by new product launches and the Erbitux rights acquisition.
- Significant R&D investment continued, with expenses totaling $5.24 billion, underscoring the company's commitment to innovation and pipeline development.
- Several key products experienced significant revenue declines due to patent expirations and generic competition, including Cymbalta (outside U.S.) and Zyprexa (Japan), highlighting a critical risk factor for investors.
- The company completed the acquisition of Novartis Animal Health's U.S. vaccine portfolio in January 2017 for approximately $885 million, strengthening its Elanco division.
- New molecular entities approved in 2016 included Taltz (psoriasis, psoriatic arthritis) and Lartruvo (soft tissue sarcoma), with several others in Phase III trials, indicating a pipeline with future growth potential.
- The company faces ongoing patent litigation for key products like Alimta and Effient, with potential for material adverse effects on future results if unfavorable outcomes occur.
- Pressures on pharmaceutical pricing and reimbursement from both public and private payers in the U.S. and internationally are expected to continue, potentially impacting future revenues.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 21, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $21.22B$19.96B | +6.3% |
| Cost of Revenue | $5.65B$5.04B | +12.3% |
| Gross Profit | $15.57B$14.92B | +4.3% |
| R&D Expenses | $5.31B$4.80B | +10.7% |
| SG&A Expenses | $6.53B$6.53B | −0.1% |
| Interest Expense | $185.20M$161.20M | +14.9% |
| Net Income | $2.74B$2.41B | +13.7% |
| EPS (Basic) | $2.59$2.27 | +14.1% |
| EPS (Diluted) | $2.58$2.26 | +14.2% |
| Shares Outstanding (Basic) | 1.06B1.06B | −0.3% |
| Shares Outstanding (Diluted) | 1.06B1.07B | −0.4% |
05—Questions
Frequently Asked Questions
What were Eli Lilly's key drivers of revenue growth in 2016?
Eli Lilly's revenue growth in 2016 was primarily driven by strong performance in the U.S. market, up 14%. This was boosted by increased sales volumes for products like Trulicity, Taltz, and Jardiance, as well as the positive impact from acquiring commercialization rights for Erbitux in the U.S. and Canada.
What are the main challenges Eli Lilly faced in 2016 regarding its product portfolio?
The company experienced significant revenue declines for products like Cymbalta (outside the U.S.) and Zyprexa (in Japan) due to the loss of patent exclusivity and subsequent generic competition. This loss of intellectual property protection is a recurring challenge that impacts revenue streams for established products.
How is Eli Lilly investing in its future growth?
Eli Lilly is making substantial investments in research and development, allocating $5.24 billion in 2016 to discover and develop new medicines. Additionally, the company is pursuing strategic acquisitions, such as the recent purchase of a vaccine portfolio for its Elanco Animal Health division, to broaden its product offerings and market reach.
What is the company's stance on patent protection and litigation?
Intellectual property protection is critical to Lilly's business model. The company actively defends its patents and is involved in ongoing litigation for key products like Alimta and Effient. Unfavorable outcomes in these cases could significantly impact future revenues, as highlighted in the report.
06—Continue